Patient perceptions of quality of life with diabetes-related complications and treatments

Diabetes Care

Volumn 30, Issue 10, 2007, Pages 2478-2483

  Huang, Elbert S ^a,b   Brown, Sydney E S ^a   Ewigman, Bernard G ^a   Foley, Edward C ^a   Meltzer, David O ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; AMPUTATION; ANGINA PECTORIS; ARTICLE; BLINDNESS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET THERAPY; FEMALE; HEALTH STATUS; HUMAN; KIDNEY DISEASE; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; RISK FACTOR; STROKE;

ADULT; AGED; ATTITUDE TO HEALTH; CHICAGO; DIABETES COMPLICATIONS; ETHNIC GROUPS; FEMALE; HEALTH STATUS; HUMANS; INTERVIEWS; MALE; MIDDLE AGED; PERCEPTION; QUALITY OF LIFE; SOCIOECONOMIC FACTORS;

EID: 35148821008     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-0499     Document Type: Article

References (27)

1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
2. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
3. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
4. Standards of medical care in diabetes - 2007. Diabetes Care 30 (Suppl. 1):S4-S41, 2007
5. Saaddine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, Imperatore G, Narayan KM: Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 144:465-474, 2006
6. Steinbrook R: Facing the diabetes epidemic-mandatory reporting of glycosylated hemoglobin values in New York City. N Engl J Med 354:545-548, 2006
7. Vijan S, Hayward RA, Ronis DL, Hofer TP: The burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med 20:479-482, 2005
8. UK: Prospective Diabetes Study Group: Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 22:1125-1136, 1999
9. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ 326:1419-1423, 2003
10. McMahon GT, Arky RA: Inhaled insulin for diabetes mellitus. N Engl J Med 356:497-502, 2007
11. Gold MR, Patrick DL, Torrance GW, Fryback DG, Hadorn DC, Kamlet MS, Daniels N, Weinstein MC: Identifying and valuing outcomes. In Cost-Effectiveness in Health and Medicine, Gold MR, Siegel JE, Russell LB, Weinstein MC, Eds. New York, Oxford University Press, 1996
12. The CDC Diabetes Cost-Effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction, for type 2 diabetes. JAMA 287:2542-2551, 2002
13. Huang ES, Jin L, Shook M, Chin MH, Meltzer DO: The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new onset diabetes. Diabetes Care 29:259-264, 2006
14. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198, 1975
15. Neumann PJ, Goldie SJ, Weinstein MC: Preference-based measures in economic evaluation in healthcare. Annu Rev Public Health 21:587-611, 2000
16. Sharma S, Oliver-Fernandez A, Bakal J, Hollands H, Brown GC, Brown MM: Utilities associated with diabetic retinopathy: results from a Canadian sample. Br J Ophthalmol 87:259-261, 2003
17. Churchill DN, Torrance GW, Taylor DW, Barnes CC, Ludwin DS, Shimizu A, Smith EKM: Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 10:14-20, 1987
18. Eckman MH, Greenfield S, Mackey WC, Wong JB, Kaplan SH, Sullivan L, Dukes K, Pauker SG: Foot infections in diabetic patients: decision and cost-effectiveness analysis. JAMA 273:712-720, 1995
19. Shin AY, Porter PJ, Wallace MC, Naglie G: Quality of life of stroke in younger individuals: utility assessment in patients with arteriovenous malformations. Stroke 28:2395-2399, 1997
20. Campeau L: Grading of angina pectoris. Circulation 54:522-523, 1976
21. American Diabetes Association: Diabetic nephropathy. Diabetes Care 26:S94-S98, 2003
22. Gage BF, Cardinalli AB, Owens DK: Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 29:1083-1091, 1998
23. Downs JR, Oster G, Santanello NC, Air Force Coronary Atherosclerosis Prevention Study Research Group: HMG CoA reductase inhibitors and quality of life. JAMA 269:3107-3108, 1993
24. Charlson ME, Pompei P, Ales KL, Mac-Kenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383, 1987
25. Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22:340-349, 2002
26. Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP, Engelgau MM, Kaplan RM, Herman WH: Valuing health-related quality of life in diabetes. Diabetes Care 25:2238-2243, 2002
27. Tengs TO, Wallace A: One thousand health-related quality-of-life estimates. Med Care 38:583-637, 2000